The present study demonstrates for the first time, using a transgenic mouse model, that n-6 and n-3 PUFA exert opposing effects on metabolic endotoxemia by modulating the endogenous expression of IAP and thereby modifying the gut microbiota, leading to differential outcomes in chronic low-grade inflammation and metabolic syndrome (Fig. 8). Here, ALPI is linked to metabolic syndrome.